Insider trade report
Open the filing on sec.gov
Cadrenal Therapeutics, Inc. (CVKD)
Nasdaq: CVKD · Pharmaceutical Preparations · Ponte Vedra, FL · filing with the SEC since 2022
The companyfiscal 2025, as filed
Revenuen/a
Net income-$13.2M-24.3%
Earnings per share$-6.64+23.9%
Operating cash flow-$12.6M-71.3%
Cash$4.0M-60.0%
Debtn/a
Shareholders’ equity$2.7M-63.2%
Shares, diluted1,993,757+63.5%
Return on equity-483.3%
The recordfrom its filings
Filings in 202656
Newest filingOct 13 · 4
Annual reportMar 31, 2026
Quarterly reportAug 13, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$500,000
Insider buys, 12 months$0.00
Patents granted0
Filer category<br>Emerging growth company
Trailing twelve months to Jun 2026Net income -$11.5MCash from operations -$10.2Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Employee stock plan registration
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Employee stock plan registration
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.